We were instructed by two global pharmaceutical companies, H. Lundbeck A/S and Takeda Pharmaceuticals, to defend an opposition filed against their patent to an antidepressant medication vortioxetine (marketed as Brintellix).
In one of the most significant patent cases of 2018/19, we fielded a 15-strong multidisciplinary team of specialist IP solicitors and patent attorneys to secure a global settlement for Alnylam Pharmaceuticals Inc.
Our biotech team brought to bear their deep scientific understanding and legal experience in patent drafting and global filing and prosecution strategy to secure commercially-focussed patent protection.